Jennifer R Brown

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Cancer Res 18:3791-802. 2012
  2. pmc A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Haematologica 98:964-70. 2013
  3. doi request reprint Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition
    Matthew S Davids
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Leuk Lymphoma 54:1823-5. 2013
  4. pmc Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
    Dan A Landau
    Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cell 152:714-26. 2013
  5. doi request reprint Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study
    Jeremy S Abramson
    Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Leuk Lymphoma 54:1915-20. 2013
  6. ncbi request reprint Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium
    Danelle F James
    Danelle F James, Januario E Castro, Andrew Greaves, Laura Z Rassenti, Thomas J Kipps, Moores Cancer Center, University of California San Diego, La Jolla, CA Lillian Werner, Jennifer R Brown, Donna Neuberg, Dana Farber Cancer Institute, Boston, MA William G Wierda, MD Anderson Cancer Center, The University of Texas, Houston, TX Jacqueline C Barrientos, Kanti R Rai, North Shore Long Island Jewish Health System, New Hyde Park, NY Amy J Johnson, The Ohio State University, Columbus, OH
    J Clin Oncol 32:2067-73. 2014
  7. pmc Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia
    Matthew S Davids
    Department of Medical Oncology, Dana Farber Cancer Institute, CLL Center, Harvard Medical School, Boston, MA 02215, USA
    Hematol Oncol Clin North Am 27:329-39. 2013
  8. ncbi request reprint Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Br J Haematol 160:608-17. 2013
  9. pmc MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells
    Shuqiang Li
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 6:e16956. 2011
  10. pmc Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization
    Sunita R Setlur
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Br J Haematol 151:336-45. 2010

Research Grants

Collaborators

Detail Information

Publications21

  1. pmc Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Cancer Res 18:3791-802. 2012
    ..We hypothesized that high-resolution genomic analysis of CLL would identify additional recurrent abnormalities associated with short time-to-first therapy (TTFT)...
  2. pmc A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Haematologica 98:964-70. 2013
    ..This study is registered at ClinicalTrials.gov (Identifier:00330252)...
  3. doi request reprint Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition
    Matthew S Davids
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Leuk Lymphoma 54:1823-5. 2013
    ..We are developing BH3 profiling as a biomarker to predict response to novel therapies such as ABT-199, and to identify resistance mechanisms to new agents being studied in CLL...
  4. pmc Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
    Dan A Landau
    Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cell 152:714-26. 2013
    ..Our study thus uncovers patterns of clonal evolution in CLL, providing insights into its stepwise transformation, and links the presence of subclones with adverse clinical outcomes...
  5. doi request reprint Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study
    Jeremy S Abramson
    Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Leuk Lymphoma 54:1915-20. 2013
    ..Oral clofarabine was well tolerated with encouraging efficacy in indolent B-cell lymphomas and mantle cell lymphomas, warranting further investigation...
  6. ncbi request reprint Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium
    Danelle F James
    Danelle F James, Januario E Castro, Andrew Greaves, Laura Z Rassenti, Thomas J Kipps, Moores Cancer Center, University of California San Diego, La Jolla, CA Lillian Werner, Jennifer R Brown, Donna Neuberg, Dana Farber Cancer Institute, Boston, MA William G Wierda, MD Anderson Cancer Center, The University of Texas, Houston, TX Jacqueline C Barrientos, Kanti R Rai, North Shore Long Island Jewish Health System, New Hyde Park, NY Amy J Johnson, The Ohio State University, Columbus, OH
    J Clin Oncol 32:2067-73. 2014
    ..In preclinical models, lenalidomide acted synergistically with rituximab. The CLL Research Consortium initiated a phase II study to evaluate this combination in treatment-naive patients...
  7. pmc Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia
    Matthew S Davids
    Department of Medical Oncology, Dana Farber Cancer Institute, CLL Center, Harvard Medical School, Boston, MA 02215, USA
    Hematol Oncol Clin North Am 27:329-39. 2013
    ..Potential biomarkers for clinical response to PI3K inhibitors such as ZAP-70, IGHV status, and CCL3 are examined. Where PI3K inhibition may fit in the evolving landscape of CLL therapy is also explored...
  8. ncbi request reprint Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Br J Haematol 160:608-17. 2013
    ....
  9. pmc MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells
    Shuqiang Li
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 6:e16956. 2011
    ..These data indicate an activated B cell status for CLL cells and suggest that the direction of change of individual miRNAs may predict clinical course in CLL...
  10. pmc Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization
    Sunita R Setlur
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Br J Haematol 151:336-45. 2010
    ..This study is the first high resolution effort to investigate and report somatic genetic differences between familial and sporadic CLL...
  11. ncbi request reprint Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase
    Matthew S Davids
    Chronic Lymphocytic Leukemia Center, Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA
    Future Oncol 10:957-67. 2014
    ..Future studies will combine ibrutinib with other promising novel agents currently in development in hematologic malignancies. ..
  12. pmc Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells
    Ute E Burkhardt
    Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 123:3756-65. 2013
    ..We conducted a prospective clinical trial to test whether vaccination with whole leukemia cells early after transplantation facilitates the expansion of leukemia-reactive T cells and thereby enhances antitumor immunity...
  13. pmc Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials
    Jennifer R Brown
    Harvard Medical School and Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Curr Hematol Malig Rep 8:1-6. 2013
    ..Registration trials have been initiated, and the difficult task that remains is to determine where in the course of CLL therapy this drug will have the greatest impact and benefit for patients...
  14. pmc MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
    Lian Xu
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Blood 121:2051-8. 2013
    ..The finding of this mutation in many IgM MGUS patients suggests that MYD88 L265P may be an early oncogenic event in WM pathogenesis...
  15. pmc Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
    Matthew S Davids
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 120:3501-9. 2012
    ....
  16. doi request reprint Insulin receptor activation in deletion 11q chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 17:2605-7. 2011
    ..Integrated genomic profiling, focused on deletion 11q, has identified elevated expression of the insulin receptor in a subgroup of CLLs and associated it with worse outcomes...
  17. doi request reprint Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia. [corrected]
    Jon E Arnason
    Harvard Medical School, Boston, MA, USA
    Hematology Am Soc Hematol Educ Program 2011:119-20. 2011
    ..In addition, your evaluation finds that she has acquired a 17p deletion...
  18. doi request reprint Targeting the B cell receptor pathway in chronic lymphocytic leukemia
    Matthew S Davids
    CLL Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Leuk Lymphoma 53:2362-70. 2012
    ..We address the development of potential biomarkers for response to these agents such as ZAP-70, IGHV status and CCL3, and discuss where these exciting new drugs may fit in the evolving landscape of CLL therapy...
  19. doi request reprint LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas
    Yong Zhang
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 120:1678-86. 2012
    ..The results of the present study highlight the therapeutic potential of anti-miR-155-mediated inhibition of miR-155 in the treatment of WM...
  20. pmc Inherited predisposition to chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Expert Rev Hematol 1:51-61. 2008
    ..In the coming years, the application of systematic genomics approaches to familial CLL should, hopefully, lead to the identification of novel loci involved in the disease...
  21. pmc SF3B1 and other novel cancer genes in chronic lymphocytic leukemia
    Lili Wang
    Cancer Vaccine Center and the Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 365:2497-506. 2011
    ..The somatic genetic basis of chronic lymphocytic leukemia, a common and clinically heterogeneous leukemia occurring in adults, remains poorly understood...

Research Grants2

  1. Genetic Alterations in Families with Multiple Lymphomas
    Jennifer Brown; Fiscal Year: 2007
    ..The research will be conducted primarily at Dana-Farber Cancer Institute and Harvard Medical School, where extensive clinical, scientific and faculty resources are available to ensure the completion of the project. ..